Botulism historical perspective: Difference between revisions
| Line 5: | Line 5: | ||
==Historical Perspective== | ==Historical Perspective== | ||
The German physician and poet Justinus Kerner called botulinum toxin sausage [[poison]], or Canadian bacon pathogen as this [[bacterium]] often causes poisoning by growing in badly handled or prepared meat products. He first conceived a possible therapeutic use of botulinum toxin. In 1870, Muller (another German physician) coined the name [[botulism]], from [[Latin]] botulus = sausage. In 1895, Emile Van Ermengem first isolated the bacterium Clostridium botulinum. In 1944, Edward Schantz cultured Clostridium botulinum and isolated the toxin, and, in 1949, Burgen's group discovered that botulinum toxin blocks [[neuromuscular]] transmission. | The German physician and poet Justinus Kerner called botulinum toxin sausage [[poison]], or Canadian bacon pathogen as this [[bacterium]] often causes poisoning by growing in badly handled or prepared meat products. He first conceived a possible therapeutic use of botulinum toxin. In 1870, Muller (another German physician) coined the name [[botulism]], from [[Latin]] botulus = sausage. In 1895, Emile Van Ermengem first isolated the bacterium Clostridium botulinum. In 1944, Edward Schantz cultured Clostridium botulinum and isolated the toxin, and, in 1949, Burgen's group discovered that botulinum toxin blocks [[neuromuscular]] transmission. | ||
=== | ===Botulinum Toxin as a Therapy=== | ||
By 1973, Alan B Scott, MD, of [[Smith-Kettlewell Institute]] used botulinum toxin type A (BTX-A) in monkey experiments, and, in 1980, he officially used BTX-A for the first time in humans to treat [[strabismus]]. In December 1989, BTX-A (BOTOX) was approved by the US [[Food and Drug Administration]] (FDA) for the treatment of [[strabismus]], [[blepharospasm]], and [[hemifacial]] [[spasm]] in patients over 12 years old. The [[cosmetic]] effect of BTX-A was initially described by [[ophthalmologist]] Jean Carruthers and [[dermatologist]] Alastair Carruthers, a husband-and-wife team working in Vancouver, Canada, although the effect had been observed by a number of independent groups. On April 15, 2002, the FDA announced the approval of botulinum toxin type A (BOTOX Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the [[eyebrows]] (glabellar lines). BTX-A has also been approved for the treatment of excessive underarm [[sweating]]. Botulinum Toxin Type B (BTX-B) received FDA approval for treatment of [[cervical]] [[dystonia]] on December 21, 2000. Trade names for BTX-B are [[Myobloc]] in the United States, and Neurobloc® in the European Union.The acceptance of BTX-A use for the treatment of [[spasticity]] and [[muscle]] pain disorders is growing, with approvals pending in many European countries and studies on [[headaches]] (including [[migraine]]), [[prostatic]] symptoms, [[asthma]], [[obesity]] and many other possible indications are ongoing. | By 1973, Alan B Scott, MD, of [[Smith-Kettlewell Institute]] used botulinum toxin type A (BTX-A) in monkey experiments, and, in 1980, he officially used BTX-A for the first time in humans to treat [[strabismus]]. In December 1989, BTX-A (BOTOX) was approved by the US [[Food and Drug Administration]] (FDA) for the treatment of [[strabismus]], [[blepharospasm]], and [[hemifacial]] [[spasm]] in patients over 12 years old. The [[cosmetic]] effect of BTX-A was initially described by [[ophthalmologist]] Jean Carruthers and [[dermatologist]] Alastair Carruthers, a husband-and-wife team working in Vancouver, Canada, although the effect had been observed by a number of independent groups. On April 15, 2002, the FDA announced the approval of botulinum toxin type A (BOTOX Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the [[eyebrows]] (glabellar lines). BTX-A has also been approved for the treatment of excessive underarm [[sweating]]. Botulinum Toxin Type B (BTX-B) received FDA approval for treatment of [[cervical]] [[dystonia]] on December 21, 2000. Trade names for BTX-B are [[Myobloc]] in the United States, and Neurobloc® in the European Union.The acceptance of BTX-A use for the treatment of [[spasticity]] and [[muscle]] pain disorders is growing, with approvals pending in many European countries and studies on [[headaches]] (including [[migraine]]), [[prostatic]] symptoms, [[asthma]], [[obesity]] and many other possible indications are ongoing. | ||
Botox is manufactured by Allergan Inc (U.S.) for both [[therapeutic]] as well as [[cosmetic]] use. The formulation is best stored at cold temperature of 2-8 degrees Celsius. Dysport is a therapeutic formulation of the type A toxin developed and manufactured in the UK and which is licensed for the treatment of [[focal dystonias]], symptoms of [[cerebral palsy]], and certain cosmetic uses in many territories world wide. | Botox is manufactured by Allergan Inc (U.S.) for both [[therapeutic]] as well as [[cosmetic]] use. The formulation is best stored at cold temperature of 2-8 degrees Celsius. Dysport is a therapeutic formulation of the type A toxin developed and manufactured in the UK and which is licensed for the treatment of [[focal dystonias]], symptoms of [[cerebral palsy]], and certain cosmetic uses in many territories world wide. | ||
===Cost of Botox=== | |||
The price of cosmetic [[Botox]] treatment varies widely based upon procedure, region, and other factors. A typical Botox injection will cost somewhere in the range of low to mid 100's. The variation will depend on where in the country the procedure is being done, how much of a demand there is for Botox in that region, and the availability of the injection. Some treatments may also cost more based on the specific treatment, for example, around a patient's eyes. This region will require more than 1 injection and will have a higher overall cost. | The price of cosmetic [[Botox]] treatment varies widely based upon procedure, region, and other factors. A typical Botox injection will cost somewhere in the range of low to mid 100's. The variation will depend on where in the country the procedure is being done, how much of a demand there is for Botox in that region, and the availability of the injection. Some treatments may also cost more based on the specific treatment, for example, around a patient's eyes. This region will require more than 1 injection and will have a higher overall cost. | ||
Revision as of 19:38, 19 December 2012
|
Botulism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Botulism historical perspective On the Web |
|
American Roentgen Ray Society Images of Botulism historical perspective |
|
Risk calculators and risk factors for Botulism historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.
Historical Perspective
The German physician and poet Justinus Kerner called botulinum toxin sausage poison, or Canadian bacon pathogen as this bacterium often causes poisoning by growing in badly handled or prepared meat products. He first conceived a possible therapeutic use of botulinum toxin. In 1870, Muller (another German physician) coined the name botulism, from Latin botulus = sausage. In 1895, Emile Van Ermengem first isolated the bacterium Clostridium botulinum. In 1944, Edward Schantz cultured Clostridium botulinum and isolated the toxin, and, in 1949, Burgen's group discovered that botulinum toxin blocks neuromuscular transmission.
Botulinum Toxin as a Therapy
By 1973, Alan B Scott, MD, of Smith-Kettlewell Institute used botulinum toxin type A (BTX-A) in monkey experiments, and, in 1980, he officially used BTX-A for the first time in humans to treat strabismus. In December 1989, BTX-A (BOTOX) was approved by the US Food and Drug Administration (FDA) for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients over 12 years old. The cosmetic effect of BTX-A was initially described by ophthalmologist Jean Carruthers and dermatologist Alastair Carruthers, a husband-and-wife team working in Vancouver, Canada, although the effect had been observed by a number of independent groups. On April 15, 2002, the FDA announced the approval of botulinum toxin type A (BOTOX Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines). BTX-A has also been approved for the treatment of excessive underarm sweating. Botulinum Toxin Type B (BTX-B) received FDA approval for treatment of cervical dystonia on December 21, 2000. Trade names for BTX-B are Myobloc in the United States, and Neurobloc® in the European Union.The acceptance of BTX-A use for the treatment of spasticity and muscle pain disorders is growing, with approvals pending in many European countries and studies on headaches (including migraine), prostatic symptoms, asthma, obesity and many other possible indications are ongoing.
Botox is manufactured by Allergan Inc (U.S.) for both therapeutic as well as cosmetic use. The formulation is best stored at cold temperature of 2-8 degrees Celsius. Dysport is a therapeutic formulation of the type A toxin developed and manufactured in the UK and which is licensed for the treatment of focal dystonias, symptoms of cerebral palsy, and certain cosmetic uses in many territories world wide.
Cost of Botox
The price of cosmetic Botox treatment varies widely based upon procedure, region, and other factors. A typical Botox injection will cost somewhere in the range of low to mid 100's. The variation will depend on where in the country the procedure is being done, how much of a demand there is for Botox in that region, and the availability of the injection. Some treatments may also cost more based on the specific treatment, for example, around a patient's eyes. This region will require more than 1 injection and will have a higher overall cost. Many people will continue to use receive Botox treatment over a long period of time, which will produce a large total financial cost.
{{#ev:youtube|RI7FVOBKTXM}}
References